Home The Word Brain My Amedeo FAQ Privacy About   


Amedeo C49

English + 你好 (nǐ hǎo) = limitless possibilities.
Start learning Mandarin Chinese today—for free, forever.

Amedeo C49 is completely free, for life. Next week: +49.


  Tuberculosis

  Free Subscription


Articles published in Int J Tuberc Lung Dis

Retrieve available abstracts of 266 articles:
HTML format



Single Articles


    May 2025
  1. AFIFAH NN, Intania R, Wijaya I, Obinata H, et al
    The interplay between TB and lung cancer: risk, prognosis and treatment dynamics.
    Int J Tuberc Lung Dis. 2025;29:243-252.
    PubMed     Abstract available


  2. DONKENG DONFACK VF, Ninkeh Nono V, Napa Tchuedji YLG, Ongboulal SM, et al
    Performances of loop-mediated isothermal amplification for TB diagnosis in children.
    Int J Tuberc Lung Dis. 2025;29:259-264.
    PubMed     Abstract available


  3. CHANI K, Athallah MA, Colquhoun S, Tsheten T, et al
    Proportions of Xpert MTB/RIF Ultra 'trace' results vary widely among different populations with presumptive TB.
    Int J Tuberc Lung Dis. 2025;29:271-277.
    PubMed     Abstract available


  4. MUSAAZI J, Sekaggya-Wiltshire C, Zawedde-Muyanja S, Kalema N, et al
    TB incidence following accelerated TB preventive treatment scale-up campaigns in Uganda.
    Int J Tuberc Lung Dis. 2025;29:253-258.
    PubMed     Abstract available


  5. TABACKMAN A, Gupte AN, Thangakunam B, Babu SP, et al
    Impact of premorbid nutritional status on TB severity.
    Int J Tuberc Lung Dis. 2025;29:265-270.
    PubMed     Abstract available


  6. MIN J, Park JE, Kim SY, Kim YY, et al
    Disability is a risk factor for 1-year mortality after TB diagnosis.
    Int J Tuberc Lung Dis. 2025;29:207-213.
    PubMed     Abstract available


  7. CHE B, Peng Y, Zheng X, Chen B, et al
    Attrition in the treatment cascade among elderly patients with multidrug-resistant TB.
    Int J Tuberc Lung Dis. 2025;29:218-226.
    PubMed     Abstract available


  8. SCHIUMA M, Colaneri M, Cattaneo D, Fusi M, et al
    Rifampicin drug monitoring in TB patients: new evidence for increased dosage?
    Int J Tuberc Lung Dis. 2025;29:202-206.
    PubMed     Abstract available


  9. MCNALLY G, Solomon D, Brown M, Capocci S, et al
    A diagnostic certainty score to support improvements in culture confirmation of TB.
    Int J Tuberc Lung Dis. 2025;29:227-230.
    PubMed     Abstract available


    March 2025
  10. CAO J, Shao G, Zhong H, Davies Forsman L, et al
    Population pharmacokinetics and dose evaluation for second-line TB drugs in patients with diabetes.
    Int J Tuberc Lung Dis. 2025;29:164-170.
    PubMed     Abstract available


  11. MULEBEKE R, Chemutai C, Mubangizi I, Balina M, et al
    Effect of community awareness, screening, diagnosis, and treatment campaigns on TB care in Uganda.
    Int J Tuberc Lung Dis. 2025;29:178-183.
    PubMed     Abstract available


  12. ZAVALA S, Kiritsy MC, Cox GM, Ahmed A, et al
    Geographic information systems analysis to focus TB screening among people born in endemic countries.
    Int J Tuberc Lung Dis. 2025;29:159-163.
    PubMed     Abstract available


  13. NASIRI MJ, Khoshdel N, Venketaraman V
    Glutathione and N-acetylcysteine in TB management.
    Int J Tuberc Lung Dis. 2025;29:171-177.
    PubMed     Abstract available


  14. NABITY SA, Moffitt AD, Mponda K, Melgar M, et al
    Urine metabolite-determined isoniazid adherence under programmatic conditions in people living with HIV.
    Int J Tuberc Lung Dis. 2025;29:97-102.
    PubMed     Abstract available


  15. TRAN HT, Nguyen CT, Nguyen HT, Godin I, et al
    Validation of a questionnaire to screen chronic obstructive respiratory diseases.
    Int J Tuberc Lung Dis. 2025;29:113-118.
    PubMed     Abstract available


  16. PONTICIELLO MN, Nanziri LM, Hennein R, Ochom E, et al
    Adaptation and validation of perceived HIV and TB stigma scales among persons with TB.
    Int J Tuberc Lung Dis. 2025;29:127-134.
    PubMed     Abstract available


  17. TRAM KH, Ong'ang'o J, Kiplimo R, Hawn TR, et al
    Mobility patterns, activity locations, and TB in Nairobi, Kenya.
    Int J Tuberc Lung Dis. 2025;29:103-112.
    PubMed     Abstract available


  18. PRIKHODCHENKO O, Arbuzova Y, Serikbayeva K, Zhakhina G, et al
    Epidemiology, detection, diagnosis and treatment of TB in children in Kazakhstan.
    Int J Tuberc Lung Dis. 2025;29:135-140.
    PubMed     Abstract available


    February 2025
  19. BOUZOUITA I, Cabibbe AM, Ghariani A, Smaoui S, et al
    First report of multidrug-resistant M. tuberculosis Beijing strain isolated from the indigenous population in Tunisia.
    Int J Tuberc Lung Dis. 2025;29:92-94.
    PubMed    


  20. LEGRAND KE, Allel K, Khan P, Hayes RJ, et al
    Contamination effects in cluster randomised trials of TB interventions.
    Int J Tuberc Lung Dis. 2025;29:47-53.
    PubMed     Abstract available


  21. MWANZA W, Lutinala M, Mundia K, Klinkenberg E, et al
    Stool-based Xpert testing for diagnosis of TB in children and critically ill adults.
    Int J Tuberc Lung Dis. 2025;29:75-79.
    PubMed     Abstract available


  22. NGUENHA D, Ndebele F, Saavedra B, Mambuque E, et al
    BMI as a predictor of progression from TB infection to active TB in PLHIV.
    Int J Tuberc Lung Dis. 2025;29:54-59.
    PubMed     Abstract available


  23. TCHAKOUNTE YOUNGUI B, Tchounga BK, Atwine D, Vasiliu A, et al
    Safety of 3-month rifampicin-isoniazid TPT in child household contacts in a community-based intervention.
    Int J Tuberc Lung Dis. 2025;29:67-74.
    PubMed     Abstract available


  24. ISLAM MN, Khan MK, Hassan J, Nahar MS, et al
    Reversible zoonotic transmission of TB from humans to dairy cattle.
    Int J Tuberc Lung Dis. 2025;29:80-87.
    PubMed     Abstract available


    January 2025
  25. AYALEW S, Wegayehu T, Wondale B, Alemayehu DH, et al
    Multigene Mycobacterium tuberculosis cell-free DNA assay.
    Int J Tuberc Lung Dis. 2025;29:13-19.
    PubMed     Abstract available


  26. MUZANYI G, Ntale M, Salata R, Joloba M, et al
    Hair isoniazid levels predict TB sputum culture conversion.
    Int J Tuberc Lung Dis. 2025;29:1-6.
    PubMed     Abstract available


  27. PRATHIKSHA G, Newtonraj A, Thiruvengadam K, Frederick A, et al
    TB prevalence is higher among smokers.
    Int J Tuberc Lung Dis. 2025;29:29-34.
    PubMed     Abstract available


    December 2024
  28. AFAQ S
    A comprehensive person-centred TB care model, from malnutrition to mental health.
    Int J Tuberc Lung Dis. 2024;28:561-563.
    PubMed     Abstract available


  29. SRIVASTAVA S, Gumbo T
    Examining effective monotherapy hypothesis for TB therapy failure and resistance emergence.
    Int J Tuberc Lung Dis. 2024;28:572-577.
    PubMed     Abstract available


  30. ALATISE MA, Narasimhan P, Gbadamosi MD, Chughtai AA, et al
    Accessibility and TB patient satisfaction in Nigeria.
    Int J Tuberc Lung Dis. 2024;28:585-591.
    PubMed     Abstract available


  31. ROSS J, Cummings MJ, Bakamutumaho B, Tokarz R, et al
    Xpert MTB/RIF Ultra enables sensitive detection of Mycobacterium tuberculosis in blood.
    Int J Tuberc Lung Dis. 2024;28:594-596.
    PubMed    


    November 2024
  32. ENGEL N, Apolosi I, Bhargava A, Bhan A, et al
    Building social equity and person-centred innovation into the end TB response.
    Int J Tuberc Lung Dis. 2024;28:517-520.
    PubMed     Abstract available


  33. SHAPIRO AN, Scott L, Moultrie H, Jacobson KR, et al
    Risk factors for and timing of presumptive recurrent TB.
    Int J Tuberc Lung Dis. 2024;28:527-533.
    PubMed     Abstract available


  34. LIN CM, Chen YL, Cheng YF, Cheng CY, et al
    Clinical characteristics and decortication outcomes of bacterial, tuberculous and fungal pleural infection.
    Int J Tuberc Lung Dis. 2024;28:541-546.
    PubMed     Abstract available


  35. CHAPMAN HEDGES KN, Scott N, Belknap R, Goldberg SV, et al
    Reasons for acceptance or nonparticipation in iAdhere: a trial of latent TB infection treatment.
    Int J Tuberc Lung Dis. 2024;28:521-526.
    PubMed     Abstract available


  36. PALMER M, van der Zalm MM, Schaaf HS, Goussard P, et al
    Approaches and processes for paediatric chest X-ray classification used in the SHINE TB treatment-shortening trial.
    Int J Tuberc Lung Dis. 2024;28:547-553.
    PubMed     Abstract available


    October 2024
  37. MALDARI A, Brigham M, Emeto TI, Adegboye O, et al
    The impact of the COVID-19 pandemic on TB in a low TB burden setting.
    Int J Tuberc Lung Dis. 2024;28:510-512.
    PubMed    


  38. VANLEEUW L, Sanchez M, Forse R, Zembe-Mkabile W, et al
    Making social protection a reality for people with TB: a perspective on new global guidance.
    Int J Tuberc Lung Dis. 2024;28:473-475.
    PubMed     Abstract available


  39. RICCARDI N, Monari C, Antonello RM, Saderi L, et al
    TB outpatient care in a high-income, low-incidence country.
    Int J Tuberc Lung Dis. 2024;28:513-515.
    PubMed    


  40. LARSSON L, Corbett C, Kalmambetova G, Utpatel C, et al
    Whole-genome sequencing drug susceptibility testing is associated with positive MDR-TB treatment response.
    Int J Tuberc Lung Dis. 2024;28:494-499.
    PubMed     Abstract available


  41. KODAMA T, Chikamatsu K, Kamada K, Mizuno K, et al
    Evaluation of testing face-mask filter samples with LAMP shows high rates of detection in pulmonary TB.
    Int J Tuberc Lung Dis. 2024;28:476-481.
    PubMed     Abstract available


  42. COLOMB S, Tricot M, Baccino E, Lesage FX, et al
    Occupational transmission of TB infection during autopsy.
    Int J Tuberc Lung Dis. 2024;28:508-509.
    PubMed    


  43. MARTINS MF, Dauphinais MR, Tabackman A, Narasimhan PB, et al
    Clearing the air: microcosting the carbon impact of drug-susceptible pulmonary TB treatment.
    Int J Tuberc Lung Dis. 2024;28:488-493.
    PubMed     Abstract available


  44. SMIRNOVA N, Bryan CS, Salindri AD, Avaliani T, et al
    Cavitary lung lesions and quality of life after TB.
    Int J Tuberc Lung Dis. 2024;28:505-507.
    PubMed    


    September 2024
  45. CEVIK M, Sturdy A, Maraolo AE, Dekkers BGJ, et al
    A systematic review on the effect of diabetes mellitus on the pharmacokinetics of TB drugs.
    Int J Tuberc Lung Dis. 2024;28:454-460.
    PubMed     Abstract available


  46. MARAIS BJ, Buck WC, Schaaf HS
    The hidden burden of miliary TB in children and adolescents.
    Int J Tuberc Lung Dis. 2024;28:407-409.
    PubMed    


  47. DECKER SR, Marchesan LQ, Silva DW, Deutschendorf C, et al
    A cohort study exploring variables associated with mortality in critically ill TB patients.
    Int J Tuberc Lung Dis. 2024;28:461-463.
    PubMed    


  48. BUONSENSO D, Mariani F, Morello R, Song R, et al
    Miliary TB in children and adolescents: a scoping review.
    Int J Tuberc Lung Dis. 2024;28:412-418.
    PubMed     Abstract available


  49. NGUYEN LN, Phan PT, Jaramillo E, Dinh A, et al
    Respiratory impairment after completion of TB treatment: a neglected but vitally important issue.
    Int J Tuberc Lung Dis. 2024;28:410-411.
    PubMed    


  50. AGUIAR A, Abreu M, Gaio R, Duarte R, et al
    Barriers to TB detection in Portuguese prisons.
    Int J Tuberc Lung Dis. 2024;28:464-466.
    PubMed    


  51. BIEWER A, Tintaya K, Roman B, Hurwitz S, et al
    Diagnostic accuracy of an exhaled breath test for TB in hospitalized patients with cough or risk.
    Int J Tuberc Lung Dis. 2024;28:446-453.
    PubMed     Abstract available


  52. ZAWEDDE J, Abelman R, Musisi E, Nyabigambo A, et al
    Lung function and health-related quality of life among adult patients following pulmonary TB treatment.
    Int J Tuberc Lung Dis. 2024;28:419-426.
    PubMed     Abstract available


  53. ARMSTRONG-HOUGH M, Shelby T, Ggita J, Nangendo J, et al
    An adapted scale to measure perceived TB and HIV stigma during household contact investigation.
    Int J Tuberc Lung Dis. 2024;28:433-438.
    PubMed     Abstract available


  54. TAKEDA K, Nagai H, Kawashima M, Kosai I, et al
    Cold temperatures during sample transportation may cause false-negative interferon-gamma release assays used to diagnose TB infection.
    Int J Tuberc Lung Dis. 2024;28:467-469.
    PubMed    


    August 2024
  55. HOOLE AS, Ilyas A, Munawar S, Cant M, et al
    Post-TB bronchiectasis: clinical characteristics and microbiology.
    Int J Tuberc Lung Dis. 2024;28:405-406.
    PubMed    


  56. JASWAL MR, Farooq S, Hussain H, Shah J, et al
    TB disease yield from household contact screening of TB index patients in Pakistan.
    Int J Tuberc Lung Dis. 2024;28:374-380.
    PubMed     Abstract available


  57. KLAOS K, Agejeva A, Hurt K, Kummik T, et al
    Prospective evaluation of thin-layer agar colour test in routine diagnosis of multidrug-resistant TB.
    Int J Tuberc Lung Dis. 2024;28:387-394.
    PubMed     Abstract available


  58. DAHL VN, Butova T, Kuzhko M, Sapelnik N, et al
    HIV remains a deadly companion to drug-resistant TB in Ukraine.
    Int J Tuberc Lung Dis. 2024;28:400-402.
    PubMed    


  59. DENHOLM JT, Coussens A, Houben RMGJ, Horton KC, et al
    The International Consensus for Early TB framework (ICE-TB): Implications from a low-incidence setting.
    Int J Tuberc Lung Dis. 2024;28:381-386.
    PubMed     Abstract available


  60. SIERRA CJ, Huang Y, Cotton SA, Hughes TD, et al
    Clinical outcomes in comorbid COVID-19 and TB cases.
    Int J Tuberc Lung Dis. 2024;28:397-399.
    PubMed    


    July 2024
  61. DYTKO O, Park M, Nicholas R, Akshikar R, et al
    Digital surveillance of ocular toxicity during TB treatment.
    Int J Tuberc Lung Dis. 2024;28:360-361.
    PubMed    


  62. HAPPAERTS M, Lorent N, Andre E
    Exploring the use of exhaled breath as a diagnostic tool for pulmonary TB.
    Int J Tuberc Lung Dis. 2024;28:317-321.
    PubMed     Abstract available


  63. LO HY, Huang YC, Chan PC, Lee CC, et al
    TB notifications among citizens and non-citizens in Taiwan.
    Int J Tuberc Lung Dis. 2024;28:328-334.
    PubMed     Abstract available


  64. SEMAKULA L, Kakai I, Zawedde-Muyanja S, Nerima P, et al
    Private pharmacy and community health worker engagement in the provision of TB services.
    Int J Tuberc Lung Dis. 2024;28:343-347.
    PubMed     Abstract available


  65. GODEFROY N, Monsel G, Jaureguiberry S, Henry B, et al
    Lessons learned from treating drug-resistant TB and how to apply these to drug-susceptible TB.
    Int J Tuberc Lung Dis. 2024;28:357-359.
    PubMed    


  66. SAVINKINA A, Muyindike W, Hahn JA, Emenyonu NI, et al
    Strategies for isoniazid preventive therapy in HIV-positive patients who consume alcohol.
    Int J Tuberc Lung Dis. 2024;28:335-342.
    PubMed     Abstract available


  67. PRATHIKSHA G, Selvaraju S, Thiruvengadam K, Frederick A, et al
    Programmatic implications of a sub-national TB prevalence survey in India.
    Int J Tuberc Lung Dis. 2024;28:348-353.
    PubMed     Abstract available


    June 2024
  68. MIN J, Kim SY, Park JE, Park JH, et al
    Did public-private partnerships reduce TB incidence in Korea?
    Int J Tuberc Lung Dis. 2024;28:306-308.
    PubMed    


  69. CHIANG SS, Jenkins HE
    Pediatric TB treatment outcomes: targets for improvement.
    Int J Tuberc Lung Dis. 2024;28:263-265.
    PubMed    


  70. DIAS JV, Varandas L, Goncalves L, Kagina B, et al
    Outcomes of childhood TB in countries with a universal BCG vaccination policy.
    Int J Tuberc Lung Dis. 2024;28:273-277.
    PubMed     Abstract available


  71. KIWANUKA N, Quach T, Kakaire R, Zalwango S, et al
    Incidence of tuberculous infection in a TB-endemic city.
    Int J Tuberc Lung Dis. 2024;28:266-272.
    PubMed     Abstract available


  72. PHELAN JE, Utpatel C, Ismail N, Cortes T, et al
    Careful classification of potential bedaquiline resistance mutations is critical when analysing their clinical impact.
    Int J Tuberc Lung Dis. 2024;28:312-313.
    PubMed    


  73. CARVALHO MM, Barbosa P, Ramos P, Vieira M, et al
    Limitations of using tuberculin skin test to screen for TB in patients with psoriasis.
    Int J Tuberc Lung Dis. 2024;28:304-305.
    PubMed    


  74. RAMOS-RINCON JM, Montoya B, Simpson G, Burgos M, et al
    An epidemiological analysis of TB trends in native and migrant populations, New Mexico, 1993-2021.
    Int J Tuberc Lung Dis. 2024;28:278-286.
    PubMed     Abstract available


  75. SHEARER K, Variava E, Kekana B, Abraham P, et al
    TB diagnoses and mortality in hospitalized people living with HIV in South Africa.
    Int J Tuberc Lung Dis. 2024;28:301-303.
    PubMed    


  76. WORDUI S, Masu A, Golden L, Chaya S, et al
    Aetiology of pleural effusions in children living in a high TB endemic setting.
    Int J Tuberc Lung Dis. 2024;28:295-300.
    PubMed     Abstract available


  77. BONGOMIN F, Denning DW
    Chronic pulmonary aspergillosis: a neglected post-TB lung disease.
    Int J Tuberc Lung Dis. 2024;28:314-315.
    PubMed    


    May 2024
  78. PATEL MA, Durovni B, Salazar-Austin N, Cavalcante SC, et al
    TB prevalence among pregnant women with HIV in Rio de Janeiro, Brazil.
    Int J Tuberc Lung Dis. 2024;28:259-261.
    PubMed    


  79. ALLAN-BLITZ LT, Yarbrough C, Ndayizigiye M, Wade C, et al
    Point-of-care ultrasound for diagnosing extrapulmonary TB.
    Int J Tuberc Lung Dis. 2024;28:217-224.
    PubMed     Abstract available


  80. RAUTMAN LH, Kammerer JS, Silk BJ, Marconi VC, et al
    Characteristics of TB cases without documented sputum culture in the United States, 2011-2021.
    Int J Tuberc Lung Dis. 2024;28:231-236.
    PubMed     Abstract available


  81. MANGAN JM, Hedges KNC, Salerno MM, Tatum K, et al
    Facilitators and barriers to adolescent participation in a TB clinical trial.
    Int J Tuberc Lung Dis. 2024;28:243-248.
    PubMed     Abstract available


  82. WADEMAN DT, Saule Z, Marthinus A, Viljoen L, et al
    Acceptability of clofazimine capsules in children and adolescents with rifampicin-resistant TB.
    Int J Tuberc Lung Dis. 2024;28:256-258.
    PubMed    


  83. DIAZ YDG, Palma D, Vargas-Leguas H, Rodrigo T, et al
    Factors associated with referrals for directly observed treatment and unsuccessful treatment.
    Int J Tuberc Lung Dis. 2024;28:237-242.
    PubMed     Abstract available


  84. MARQUES MS, Silva T, Gomes A, Pereira C, et al
    Factors associated with patient delay in the diagnosis of TB - a study of health-seeking behaviour.
    Int J Tuberc Lung Dis. 2024;28:249-252.
    PubMed    


    April 2024
  85. PARREIRA PL, Fonseca AU, Soares F, Conte MB, et al
    Chest X-ray evaluation using machine learning to support the early diagnosis of pulmonary TB.
    Int J Tuberc Lung Dis. 2024;28:171-175.
    PubMed     Abstract available


  86. DOGO FM, Ate S, Agossou K, Menon S, et al
    Decentralising DOT for drug-susceptible TB from the health facilities to the community level in Togo.
    Int J Tuberc Lung Dis. 2024;28:195-201.
    PubMed     Abstract available


  87. ILAIWY G, Heysell SK, Lukumay S, Agustino D, et al
    Cash transfers to enhance completion of TB screening among household contacts in rural Tanzania.
    Int J Tuberc Lung Dis. 2024;28:176-182.
    PubMed     Abstract available


  88. MARKS SM, Winston CA
    Estimated treatment costs for multidrug-resistant TB in the United States.
    Int J Tuberc Lung Dis. 2024;28:214-215.
    PubMed    


  89. KAWATSU L, Uchimura K, Schwalb A, Houben R, et al
    New perspectives on the secular trend in pulmonary TB in post-war Japan (1953-1980).
    Int J Tuberc Lung Dis. 2024;28:207-209.
    PubMed    


  90. SHAIKH A, Sriraman K, Vaswani S, Shah I, et al
    SMaRT-PCR: sampling using masks and RT-PCR, a non-invasive diagnostic tool for paediatric pulmonary TB.
    Int J Tuberc Lung Dis. 2024;28:189-194.
    PubMed     Abstract available


    March 2024
  91. OTA M, Hirao S, Uchimura K
    Lower TB notification rates in later life in the same birth cohort, Japan, 1950-2020.
    Int J Tuberc Lung Dis. 2024;28:157-159.
    PubMed    


  92. PONTALI E, Akkerman OW, Zenner D, Migliori GB, et al
    Post-TB lung disease: keep going beyond TB!
    Int J Tuberc Lung Dis. 2024;28:113-114.
    PubMed    


  93. THEKKUR P, Thiagesan R, Nair D, Karunakaran N, et al
    Using timeliness metrics for household contact tracing and TB preventive therapy in the private sector, India.
    Int J Tuberc Lung Dis. 2024;28:122-139.
    PubMed     Abstract available


  94. SOUSA S, Santos S, Alves CM, Goncalves G, et al
    Impact of annual TB screening on stone quarry workers in high-incidence Portuguese municipalities.
    Int J Tuberc Lung Dis. 2024;28:136-141.
    PubMed     Abstract available


  95. THOMSON H, Baines N, Huisamen T, Koegelenberg CFN, et al
    A new understanding of clinical patterns in post-TB lung disease.
    Int J Tuberc Lung Dis. 2024;28:115-121.
    PubMed     Abstract available


  96. LEVER S, Akkerman OW, Dekkers BGJ
    Pancreatitis delays the absorption of first-line anti-TB drugs.
    Int J Tuberc Lung Dis. 2024;28:163-165.
    PubMed    


  97. YAMKOVOY K, Self JL, Jenkins HE, Horsburgh CR, et al
    Patterns of TB transmission in the United States, 2011-2017.
    Int J Tuberc Lung Dis. 2024;28:154-156.
    PubMed    


  98. REZAEE M, Azizi N, Danaei B, Davari A, et al
    TB and interstitial lung disease: a systematic review and meta-analysis.
    Int J Tuberc Lung Dis. 2024;28:130-135.
    PubMed     Abstract available


  99. RUDOLF F, Abate E, Moges B, Gomes VF, et al
    A structured 2-week follow-up visit in the cascade of care for TB increases case detection.
    Int J Tuberc Lung Dis. 2024;28:148-153.
    PubMed     Abstract available


  100. LEAVITT SV, Rodriguez CA, Bouton TC, Horsburgh CR, et al
    Outcomes for people with TB by disease severity at presentation.
    Int J Tuberc Lung Dis. 2024;28:142-147.
    PubMed     Abstract available


    February 2024
  101. SILVA DR, Santos AP, Visca D, Bombarda S, et al
    The potential for vaccines to aid the treatment of post-TB lung disease.
    Int J Tuberc Lung Dis. 2024;28:44-45.
    PubMed    


  102. LONG R, Heffernan C, Lau A
    Emphasis on post-TB lung disease and other sequelae of TB is good but a public health approach to TB is morally ambitious???
    Int J Tuberc Lung Dis. 2024;28:1-3.
    PubMed    


  103. FEKADU G, Wang Y, You JHS
    Cost-effectiveness of pretomanid-based regimen for highly drugresistant TB in a low-burden setting.
    Int J Tuberc Lung Dis. 2024;28:12-17.
    PubMed     Abstract available


  104. TURNER RD, Birring SS, Bothamley GH
    Measuring cough-related quality of life and cough frequency in pulmonary TB.
    Int J Tuberc Lung Dis. 2024;28:25-31.
    PubMed     Abstract available


  105. SHIN JE, Jeon D, Mok J, Yim JJ, et al
    Compliance with new drug use and the effect of discrepant drug susceptibility testing on MDR/RR-TB treatment.
    Int J Tuberc Lung Dis. 2024;28:18-24.
    PubMed     Abstract available


  106. DOLEZALOVA K, Kika V, Wallenfels J
    Increasing incidence of TB in a low burden TB country due to migration from Ukraine.
    Int J Tuberc Lung Dis. 2024;28:39-40.
    PubMed    


  107. NIGHTINGALE ES, Feasey HRA, Khundi M, Soko RN, et al
    Community-level variation in TB testing history in Blantyre, Malawi.
    Int J Tuberc Lung Dis. 2024;28:32-38.
    PubMed     Abstract available


    January 2024
  108. YILDIRIM K, Bozkurt S, Basibuyuk HH, Coban AY, et al
    Anti-tuberculosis activity of morusin: a promising flavonoid from white mulberry.
    Int J Tuberc Lung Dis. 2024;28:37-41.
    PubMed     Abstract available


  109. KUMAR SR, Hissar SS, Ramesh PM, Shanmugam M, et al
    Ethambutol-induced optic neuropathy: should we mandate ophthalmic examination in TB treatment?
    Int J Tuberc Lung Dis. 2024;28:51-53.
    PubMed    


  110. SURIE D, Sathyanarayanan MK, Lavanya J, Smith JP, et al
    Long-term follow-up of persons diagnosed with multidrug-resistant TB in Chennai, India, 2013-2020.
    Int J Tuberc Lung Dis. 2024;28:54-56.
    PubMed    


  111. RICCARDI N, Antonello RM, Besozzi G, Tadolini M, et al
    Ten common myths about drug-susceptible TB.
    Int J Tuberc Lung Dis. 2024;28:61-64.
    PubMed    


  112. DU Y, Gu J, Yang Y, Chen Y, et al
    Efficacy and safety of bicyclol for treating patients with antituberculosis drug-induced liver injury.
    Int J Tuberc Lung Dis. 2024;28:6-12.
    PubMed     Abstract available


  113. BEELER ASAY GR, Woodruff R, Sanderson DM, Fisher CF, et al
    Cost-effectiveness of expanded latent TB infection testing and treatment: Lynn City, Massachusetts, USA.
    Int J Tuberc Lung Dis. 2024;28:21-28.
    PubMed     Abstract available


  114. SCHILDKRAUT JA, Sloan D, Boeree MJ
    If you want to go far, go together: standardisation and data sharing in TB drug development.
    Int J Tuberc Lung Dis. 2024;28:3-5.
    PubMed    


  115. HOUBEN RMGJ, McCaffrey T, Tiemersma EW, Khan PY, et al
    Estimating TB survival - mind the immortal-time gap.
    Int J Tuberc Lung Dis. 2024;28:65-66.
    PubMed    


  116. YUAN S, Cui Y, Shang Y, Su F, et al
    Prevalence, temporal trends and risk factors of drug-resistant TB in Zibo, China, 2018-2021.
    Int J Tuberc Lung Dis. 2024;28:57-58.
    PubMed    


  117. GEIGER K, Patil A, Bergman A, Budhathoki C, et al
    Exploring HIV disease indicators at MDR-TB treatment initiation in South Africa.
    Int J Tuberc Lung Dis. 2024;28:42-50.
    PubMed     Abstract available


  118. OLIVEIRA DA SILVA B, Salindri AD, Goncalves TO, Cunha EAT, et al
    The impact of sputum quality on Xpert positivity in active case-finding for TB.
    Int J Tuberc Lung Dis. 2024;28:29-36.
    PubMed     Abstract available


  119. TYUFEKCHIEVA M, Varleva T
    Monitoring TB infection in contact cases: the impact of the COVID-19 pandemic.
    Int J Tuberc Lung Dis. 2024;28:59-60.
    PubMed    


    December 2023
  120. YANG H, Antwi S, Maranchick N, Dompreh A, et al
    Effect of HIV infection on plasma exposure to first-line TB drugs and target attainment in children.
    Int J Tuberc Lung Dis. 2023;27:931-937.
    PubMed     Abstract available


  121. MAKEK MJ, Trauer JM, Blackbourn HD
    Literature Highlights.
    Int J Tuberc Lung Dis. 2023;27:882-884.
    PubMed     Abstract available


  122. ARAUJO-PEREIRA M, Andrade BB
    Atorvastatin to reduce bacillary load and attenuate lung damage in TB patients.
    Int J Tuberc Lung Dis. 2023;27:880-881.
    PubMed    


  123. COMMIESIE E, Stijnberg D, van den Boogaard J, Gopie F, et al
    Challenges and opportunities for TB elimination in Suriname.
    Int J Tuberc Lung Dis. 2023;27:946-948.
    PubMed    


  124. RAGHEB SM, White JB, Jarand J, Fisher DA, et al
    Assessing patient satisfaction with video-supported therapy for drug-susceptible TB treatment.
    Int J Tuberc Lung Dis. 2023;27:938-940.
    PubMed    


  125. CHUNG C, Jo KW, Shim TS
    Treatment outcome, recurrence and safety of multidrug-resistant TB treated with low-dose linezolid.
    Int J Tuberc Lung Dis. 2023;27:918-924.
    PubMed     Abstract available


  126. DU CROS P, Greig J, Alffenaar JC, Cross GB, et al
    Standards for clinical trials for treating TB.
    Int J Tuberc Lung Dis. 2023;27:885-898.
    PubMed     Abstract available


  127. ADEWOLE OO, Omotoso BA, Ogunsina M, Aminu A, et al
    Atorvastatin improves sputum conversion and chest X-ray severity score.
    Int J Tuberc Lung Dis. 2023;27:912-917.
    PubMed     Abstract available


  128. QUINCER EM, Lyland A, Onyango D, LaCourse SM, et al
    The effect of antenatal isoniazid preventive therapy on birth outcomes in Western Kenya.
    Int J Tuberc Lung Dis. 2023;27:906-911.
    PubMed     Abstract available


  129. NETO ERD, Matos TS, Ferreira ACF, Bezerra-Santos M, et al
    The impact of COVID-19 on TB care in Brazil.
    Int J Tuberc Lung Dis. 2023;27:941-943.
    PubMed    


  130. MENDOZA-TICONA A, Mitnick CD, Obregon G, Alarcon V, et al
    Screening with GenoType((R)) MTBDRplus shortens the time to MDR-TB treatment initiation but does not change outcomes.
    Int J Tuberc Lung Dis. 2023;27:949-951.
    PubMed    


  131. KIBIRIGE D, Andia-Biraro I, Olum R, Adakun S, et al
    Metabolic characterisation of adult Ugandan patients with TB and diabetes mellitus comorbidity.
    Int J Tuberc Lung Dis. 2023;27:944-945.
    PubMed    


    November 2023
  132. EDWARDS S, Humbert T, Berdzuli N, Azzopardi-Muscat N, et al
    Tackling TB in Europe: treatment gaps and deteriorating treatment availability is undermining progress.
    Int J Tuberc Lung Dis. 2023;27:793-796.
    PubMed    


  133. MARGINEANU I, Butnaru T, Gafar F, Baiceanu D, et al
    TB therapeutic drug monitoring - analysis of opportunities in Romania and Ukraine.
    Int J Tuberc Lung Dis. 2023;27:816-821.
    PubMed     Abstract available


  134. KATRAK S, Wang R, Barry P
    Costs of treating multidrug-resistant TB in California in 2022.
    Int J Tuberc Lung Dis. 2023;27:864-866.
    PubMed    


  135. TANEJA R, Nahata MC, Scarim J, Pande PG, et al
    A novel home-based method for preparing suspensions of anti-TB drugs.
    Int J Tuberc Lung Dis. 2023;27:810-815.
    PubMed     Abstract available


  136. INBARAJ LR, Rade K, Selvaraju S, Rao R, et al
    Mortality estimates of central nervous system TB in India.
    Int J Tuberc Lung Dis. 2023;27:876-877.
    PubMed    


  137. FRITSCHI N, Vaezipour N, Buettcher M, Portevin D, et al
    Ratios from full blood count as markers for TB diagnosis, treatment, prognosis: a systematic review.
    Int J Tuberc Lung Dis. 2023;27:822-832.
    PubMed     Abstract available


    October 2023
  138. ANDREWS F, Welch S, Scandrett K, Kaur H, et al
    Outcomes of TB contact tracing and predictors of success: a 10-year retrospective cohort analysis in Birmingham, UK.
    Int J Tuberc Lung Dis. 2023;27:766-771.
    PubMed     Abstract available


  139. TRAUER JM, Tiberi S, Graham SM, Blackbourn HD, et al
    Literature Highlights.
    Int J Tuberc Lung Dis. 2023;27:721-723.
    PubMed     Abstract available


  140. NELSON KN, Shah NS, Cranmer LM, Vasudevan L, et al
    An effective vaccine is only the first step: the need to create and sustain demand for TB vaccines.
    Int J Tuberc Lung Dis. 2023;27:718-720.
    PubMed    


  141. PUMA D, Geadas C, Calderon RI, Yuen CM, et al
    Active case-finding for TB among incarcerated women in Peru.
    Int J Tuberc Lung Dis. 2023;27:784-786.
    PubMed    


  142. AKKERMAN OW, Dijkwel RDC, Kerstjens HAM, van der Werf TS, et al
    Isoniazid and rifampicin exposure during treatment in drug-susceptible TB.
    Int J Tuberc Lung Dis. 2023;27:772-777.
    PubMed     Abstract available


  143. CHIANG SS, Zeng C, Roman-Sinche B, Altamirano E, et al
    Adaptation and validation of a TB stigma scale for adolescents in Lima, Peru.
    Int J Tuberc Lung Dis. 2023;27:754-760.
    PubMed     Abstract available


  144. KIM JY, Koo B, Lim SY, Cha HH, et al
    A non-invasive, sensitive assay for active TB: combined cell-free DNA detection and FluoroSpot assays.
    Int J Tuberc Lung Dis. 2023;27:790-792.
    PubMed    


  145. REKART ML, Aung A, Cullip T, Mulanda W, et al
    Household drug-resistant TB contact tracing in Tajikistan.
    Int J Tuberc Lung Dis. 2023;27:748-753.
    PubMed     Abstract available


  146. RAJAVARDHANA T, Koushik MR, Jayakumar C, Ramalingam P, et al
    Adherence to treatment on a daily-dose regimen for TB.
    Int J Tuberc Lung Dis. 2023;27:778-780.
    PubMed    


  147. SINGH UB, Ray Y, Kanswal S, Sharma HP, et al
    Low rifampicin levels in plasma associated with a poor clinical response in patients with abdominal TB.
    Int J Tuberc Lung Dis. 2023;27:787-789.
    PubMed    


  148. FRAZIER C, Nabity SA, Flood J
    Incidence of TB disease among persons who use drugs in California.
    Int J Tuberc Lung Dis. 2023;27:781-783.
    PubMed    


  149. RAJENDRAN P, Saini S, Kumar N, Vashistha H, et al
    Establishing proof of concept for utility of Trueprep((R))-extracted DNA in line-probe assay testing.
    Int J Tuberc Lung Dis. 2023;27:742-747.
    PubMed     Abstract available


    September 2023
  150. MACHAVARIANI E, Nonyane BAS, Lebina L, Mmolawa L, et al
    Perceived stigma among people with TB and household contacts.
    Int J Tuberc Lung Dis. 2023;27:675-681.
    PubMed     Abstract available


  151. VILJOEN L, Acaba J, Agbassi YJP, Beko B, et al
    Community perspective on child-friendly medications for drug-resistant TB: importance, priorities and advocacy.
    Int J Tuberc Lung Dis. 2023;27:655-657.
    PubMed    


  152. RODRIGUEZ CA, Leavitt SV, Bouton TC, Horsburgh CR, et al
    Survival of people with untreated TB: effects of time, geography and setting.
    Int J Tuberc Lung Dis. 2023;27:694-702.
    PubMed     Abstract available


  153. BECKER GL, Amuge P, Ssebunya R, Motevalli M, et al
    Predictors of mortality in Ugandan children with TB, 2016-2021.
    Int J Tuberc Lung Dis. 2023;27:668-674.
    PubMed     Abstract available


  154. DO NASCIMENTO DR, Serpa SF, Bezerra-Santos M, do Carmo RF, et al
    The impact of the COVID-19 pandemic on TB diagnosis in the Brazilian prison population, 2020-2021.
    Int J Tuberc Lung Dis. 2023;27:688-693.
    PubMed     Abstract available


  155. GALEA JT, Chu AL, Sweetland AC, Jimenez J, et al
    Latent TB and depressive symptoms in household contacts of persons with active TB.
    Int J Tuberc Lung Dis. 2023;27:682-687.
    PubMed     Abstract available


    August 2023
  156. SILVA DR, Munoz-Torrico M, Fernandes GR, Narvaez-Diaz L, et al
    Isoniazid-resistant TB: treatment outcomes and impact of regimens with fluoroquinolones.
    Int J Tuberc Lung Dis. 2023;27:638-640.
    PubMed    


  157. AHMED S, Lotia-Farrukh I, Khan PY, Adnan S, et al
    High prevalence of multidrug-resistant TB among household contacts in a high burden setting.
    Int J Tuberc Lung Dis. 2023;27:646-648.
    PubMed    


  158. CHIANG SS, Graham SM, Schaaf HS, Marais BJ, et al
    Clinical standards for drug-susceptible TB in children and adolescents.
    Int J Tuberc Lung Dis. 2023;27:584-598.
    PubMed     Abstract available


  159. MAKEK MJ, Amorim GGC, Ragonnet R, Blackbourn HD, et al
    Literature Highlights.
    Int J Tuberc Lung Dis. 2023;27:581-583.
    PubMed     Abstract available


  160. ACUNA-VILLAORDUNA C, Jacobson KR, Horsburgh CR, Canning M, et al
    Initial experience with BPaL-based regimens to treat multidrug-resistant TB.
    Int J Tuberc Lung Dis. 2023;27:649-650.
    PubMed    


  161. HACKER B, Breuer C, Priwitzer M, Otto-Knapp R, et al
    TB screening of Ukrainian refugees in Germany.
    Int J Tuberc Lung Dis. 2023;27:641-642.
    PubMed    


  162. HONGPRASIT P, Sonthisombat P
    Assessment of TB treatment adherence using computer-assisted self-interviewing.
    Int J Tuberc Lung Dis. 2023;27:626-631.
    PubMed     Abstract available


  163. RIKHOTSO MC, Ledwaba SE, Ngandu JK, Mavumengwana V, et al
    Favourable outcomes in RR-TB patients using BPaL and other WHO-recommended second-line anti-TB drugs.
    Int J Tuberc Lung Dis. 2023;27:599-605.
    PubMed     Abstract available


  164. MARITZ ER, Montepiedra G, Mitchell CD, Madhi SA, et al
    Predictors of TB disease in HIV-exposed children from Southern Africa.
    Int J Tuberc Lung Dis. 2023;27:619-625.
    PubMed     Abstract available


  165. CHIBOLELA M, de Haas P, Klinkenberg E, Kosloff B, et al
    Use of stool swabs in molecular transport media increases access to Xpert Ultra testing for TB in children.
    Int J Tuberc Lung Dis. 2023;27:612-618.
    PubMed     Abstract available


  166. HABIB SS, Uzair M, Dhanwani A, Sohail K, et al
    A model for integrating social protection measures with TB control in Pakistan.
    Int J Tuberc Lung Dis. 2023;27:651-652.
    PubMed    


  167. RACHOW A, Ivanova O, Bakuli A, Khosa C, et al
    Performance of spirometry assessment at TB diagnosis.
    Int J Tuberc Lung Dis. 2023;27:850-857.
    PubMed     Abstract available


  168. SALERNO MM, Burzynski J, Mangan JM, Hill A, et al
    Adverse events among persons with TB using in-person vs. electronic directly observed therapy.
    Int J Tuberc Lung Dis. 2023;27:833-840.
    PubMed     Abstract available


  169. OWOLABI OA, Sillah AK, Loum I, Touray A, et al
    Factors associated with presenting to private sector care providers at the onset of TB symptoms.
    Int J Tuberc Lung Dis. 2023;27:867-868.
    PubMed    


  170. SILVESTRE CR, Cavaco M, Afonso R, Alves S, et al
    TB infection in healthcare workers - the reality of a Portuguese hospital.
    Int J Tuberc Lung Dis. 2023;27:874-875.
    PubMed    


  171. CHO MM, Kim HW, Kim JS, Min J, et al
    TB in ageing populations: lessons from Japan and Korea.
    Int J Tuberc Lung Dis. 2023;27:869-871.
    PubMed    


    July 2023
  172. NUR N, Sharif AB, Mitra DK
    Stress resilience in patients with drug-resistant TB.
    Int J Tuberc Lung Dis. 2023;27:551-556.
    PubMed     Abstract available


  173. OKOYA F, Huang CC, Zhang Z, Lecca L, et al
    Culture-negative TB: clinical characteristics, risk factors and treatment outcomes.
    Int J Tuberc Lung Dis. 2023;27:557-563.
    PubMed     Abstract available


  174. ESCALANTE P, Vadiyala MR, Pathakumari B, Marty PK, et al
    New diagnostics for the spectrum of asymptomatic TB: from infection to subclinical disease.
    Int J Tuberc Lung Dis. 2023;27:499-505.
    PubMed     Abstract available


  175. STRAUSS M, Wademan DT, Mcinziba A, Hoddinott G, et al
    TB preventive therapy preferences among children and adolescents.
    Int J Tuberc Lung Dis. 2023;27:520-529.
    PubMed     Abstract available


  176. HARRIES AD, Lin Y, Thekkur P, Nair D, et al
    Why TB programmes should assess for comorbidities, determinants and disability at the start and end of TB treatment.
    Int J Tuberc Lung Dis. 2023;27:495-498.
    PubMed    


  177. GLOGOWSKA A, Przybylski G, Bukowski J, Dolska E, et al
    TB and COVID-19 co-infection in a pulmonology hospital.
    Int J Tuberc Lung Dis. 2023;27:574-576.
    PubMed    


  178. FERRARESE M, Antonello RM, Torri S, Saderi L, et al
    Extrapulmonary TB: a 30-year observational study of an Italian cohort.
    Int J Tuberc Lung Dis. 2023;27:564-566.
    PubMed    


  179. WADEMAN DT, Viljoen L, Jacobs S, Meyerson K, et al
    Children s priorities to improve the acceptability of MDR-TB treatment: qualitative data from South Africa.
    Int J Tuberc Lung Dis. 2023;27:543-550.
    PubMed     Abstract available


  180. SINGH KP, Carvalho ACC, Centis R, D Ambrosio L, et al
    Clinical standards for the management of adverse effects during treatment for TB.
    Int J Tuberc Lung Dis. 2023;27:506-519.
    PubMed     Abstract available


  181. MARQUES J, Rocha JV, Soares P, Leite A, et al
    The effect of TB patient delay on loss to follow-up in Portugal.
    Int J Tuberc Lung Dis. 2023;27:537-542.
    PubMed     Abstract available


  182. CENTENO HURTADO KT, Garcia Bohorquez DF, Ruiz Gonzalez CE, Masias Leon Y, et al
    The burden of chronic obstructive pulmonary disease among hospitalised women in a developing country.
    Int J Tuberc Lung Dis. 2023;27:530-536.
    PubMed     Abstract available


  183. VENGURLEKAR D, Walker C, Mahajan R, Dalal A, et al
    Linezolid resistance in patients with drug-resistant TB.
    Int J Tuberc Lung Dis. 2023;27:567-569.
    PubMed    


  184. ZUREIGAT H, Alhusban M, Nawaiseh M, Alomari L, et al
    Steps towards TB elimination in Jordan.
    Int J Tuberc Lung Dis. 2023;27:576-577.
    PubMed    


    June 2023
  185. DE VRIES G, Akkerman O, Boeree M, van Hest R, et al
    Diagnosis, treatment and transmission of rifampicin-resistant TB in the Netherlands, 2010-2019.
    Int J Tuberc Lung Dis. 2023;27:471-477.
    PubMed     Abstract available


  186. MALHOTRA A, Mukiibi J, Kitonsa PJ, Nalutaaya A, et al
    Higher yield using an event-based vs. door-to-door approach for active case-finding for TB.
    Int J Tuberc Lung Dis. 2023;27:484-486.
    PubMed    


  187. MAKEK MJ, Tiberi S, Felker I, Amorim GGC, et al
    Literature Highlights.
    Int J Tuberc Lung Dis. 2023;27:429-431.
    PubMed     Abstract available


  188. NI N, Wang N, Veronese V, Wang MZ, et al
    Current status and future prospects of TB digital treatment adherence technology use in China.
    Int J Tuberc Lung Dis. 2023;27:438-443.
    PubMed     Abstract available


  189. KIM SH, Yoo JY, Cho HS, Kim SR, et al
    Clinical and imaging features of drug-susceptible and multidrug-resistant TB in Korean adults.
    Int J Tuberc Lung Dis. 2023;27:487-489.
    PubMed    


  190. LOUIE JK, Keh C, Agraz-Lara R, Phillips A, et al
    Highlighting the characteristics of TB disease in older people.
    Int J Tuberc Lung Dis. 2023;27:478-480.
    PubMed    


  191. SUNG J, Musinguzi A, Kadota JL, Baik Y, et al
    Understanding patient-level costs of weekly isoniazid-rifapentine (3HP) among people living with HIV in Uganda.
    Int J Tuberc Lung Dis. 2023;27:458-464.
    PubMed     Abstract available


  192. OESER C, Rangaka MX, Abubakar I
    Digital approaches to reducing TB treatment loss to follow-up.
    Int J Tuberc Lung Dis. 2023;27:432-437.
    PubMed     Abstract available


  193. RICH ML, Khan U, Zeng C, LaHood A, et al
    Outcomes of WHO-conforming, longer, all-oral multidrug-resistant TB regimens and analysis implications.
    Int J Tuberc Lung Dis. 2023;27:451-457.
    PubMed     Abstract available


  194. MYERS B, Carney T, Rooney J, Malatesta S, et al
    Smoked drug use in patients with TB is associated with higher bacterial burden.
    Int J Tuberc Lung Dis. 2023;27:444-450.
    PubMed     Abstract available


  195. OTAALO B, Cevik M, Mwebesa E, Nabisere-Arinaitwe R, et al
    Prevalence of COVID-19 infection in TB clinics in Kampala, Uganda.
    Int J Tuberc Lung Dis. 2023;27:481-483.
    PubMed    


    May 2023
  196. GUNTHER G, Guglielmetti L, Leu C, van Leth F, et al
    Relative cost of multidrug-resistant TB medicines in Europe.
    Int J Tuberc Lung Dis. 2023;27:341-344.
    PubMed    


  197. KWARA A, Yang H, Martyn-Dickens C, Enimil A, et al
    Adequacy of WHO weight-band dosing and fixed-dose combinations for the treatment of TB in children.
    Int J Tuberc Lung Dis. 2023;27:401-407.
    PubMed     Abstract available


  198. GIRIDHARAN P, Devaleenal B, Thiruvengadam K, Kaleeswari M, et al
    A novel method for contact tracing for TB at household and community level.
    Int J Tuberc Lung Dis. 2023;27:414-415.
    PubMed    


  199. SADERI L, Cabibbe AM, Puci M, Di Lorenzo B, et al
    A systematic review of the costs of diagnosis for multidrug-resistant/extensively drug-resistant TB in different settings.
    Int J Tuberc Lung Dis. 2023;27:348-356.
    PubMed     Abstract available


  200. GERIC C, Qin ZZ, Denkinger CM, Kik SV, et al
    The rise of artificial intelligence reading of chest X-rays for enhanced TB diagnosis and elimination.
    Int J Tuberc Lung Dis. 2023;27:367-372.
    PubMed     Abstract available


  201. FAJER EB, Costa FD, Pelissari DM, Diaz Quijano FA, et al
    Use of rapid molecular TB diagnostics for incarcerated people in Brazil.
    Int J Tuberc Lung Dis. 2023;27:416-418.
    PubMed    


  202. KASWASWA K, Mlauzi L, Mpunga J, Mandambwe C, et al
    Use of local data to evaluate TB contact investigation in Malawi.
    Int J Tuberc Lung Dis. 2023;27:408-410.
    PubMed    


  203. TANG J, Tang Z, Feng C, Tang Q, et al
    Efficacy and safety of video-assisted thoracoscopic surgery for pulmonary TB.
    Int J Tuberc Lung Dis. 2023;27:387-394.
    PubMed     Abstract available


  204. MAUGANS C, Loveday M, Hlangu S, Waitt C, et al
    Best practices for the care of pregnant people living with TB.
    Int J Tuberc Lung Dis. 2023;27:357-366.
    PubMed     Abstract available


  205. TAGUIBAO C, Lailo JM, Neukom J, Gones V, et al
    Digital survey results on pharmacy access to fixed-dose combination drugs for TB in Indonesia.
    Int J Tuberc Lung Dis. 2023;27:422-424.
    PubMed    


  206. MOE S, Rekart ML, Hernandez D, Sholpan A, et al
    Primary bedaquiline resistance in Karakalpakstan, Uzbekistan.
    Int J Tuberc Lung Dis. 2023;27:381-386.
    PubMed     Abstract available


  207. AHMED R, Osman N, Noory B, Osman R, et al
    Prevalence and determinants of chronic respiratory diseases in adults in Sudan.
    Int J Tuberc Lung Dis. 2023;27:373-380.
    PubMed     Abstract available


  208. PAREDES JL, Picon V, Reynolds L, Ugarte-Gil C, et al
    Impact of the COVID-19 pandemic on TB care in Peru.
    Int J Tuberc Lung Dis. 2023;27:411-413.
    PubMed    


  209. MUTEMBA CM, Schindele A, Munyangaju I, Ramanlal N, et al
    Contribution of Xpert((R)) MTB/RIF to pediatric TB diagnosis in Mozambique.
    Int J Tuberc Lung Dis. 2023;27:419-421.
    PubMed    


    April 2023
  210. GRIJOTA-CAMINO MD, Perez-Recio S, Trapero C, Luque MJ, et al
    Identifying gaps in the cascade of care for latent TB infection in a low-incidence setting.
    Int J Tuberc Lung Dis. 2023;27:315-321.
    PubMed     Abstract available


  211. VELEN K, Nguyen TA, Pham CD, Le HT, et al
    The effect of medication event reminder monitoring on treatment adherence of TB patients.
    Int J Tuberc Lung Dis. 2023;27:322-328.
    PubMed     Abstract available


  212. BOLHUIS MS, Akkerman OW, Sturkenboom MGG, van Boven JFM, et al
    Bedaquiline exposure in people with drug-resistant TB treated for diabetes: analysis of two phase 2 trials.
    Int J Tuberc Lung Dis. 2023;27:335-337.
    PubMed    


  213. GOLETTI D, Pisapia R, Fusco FM, Aiello A, et al
    Epidemiology, pathogenesis, clinical presentation and management of TB in patients with HIV and diabetes.
    Int J Tuberc Lung Dis. 2023;27:284-290.
    PubMed     Abstract available


  214. MIGLIORI GB, Blackbourn HD
    Post-TB lung disease - the rationale for a Clinical Statement.
    Int J Tuberc Lung Dis. 2023;27:243-244.
    PubMed    


  215. CAMPBELL JR, Chan ED, Anderson LF, Bonnet M, et al
    Association of smoking and alcohol use with rifampin-resistant TB treatment outcomes.
    Int J Tuberc Lung Dis. 2023;27:338-340.
    PubMed    


  216. SACHDEVA KS, Bhatnagar AK, Bhaskar A, Singla N, et al
    QTc prolongation with bedaquiline treatment for drug-resistant pulmonary TB in a programmatic setting.
    Int J Tuberc Lung Dis. 2023;27:329-331.
    PubMed    


  217. KAZIBWE A, Kyazze AP, Ssekamatte P, Mutebi EI, et al
    TB infection in adults with diabetes mellitus in Uganda.
    Int J Tuberc Lung Dis. 2023;27:308-314.
    PubMed     Abstract available


  218. NIGHTINGALE R, Carlin F, Meghji J, McMullen K, et al
    Post-TB health and wellbeing.
    Int J Tuberc Lung Dis. 2023;27:248-283.
    PubMed     Abstract available


  219. MANGAN JM, Burzynski J, deCastro BR, Salerno MM, et al
    Challenges associated with electronic and in-person directly observed therapy during a randomized trial.
    Int J Tuberc Lung Dis. 2023;27:298-307.
    PubMed     Abstract available


  220. KINTU TM, Mwanahamisi BS, Muwanguzi M, Kyagambiddwa T, et al
    Unfavorable treatment outcomes among patients with drug-resistant TB in Uganda.
    Int J Tuberc Lung Dis. 2023;27:291-297.
    PubMed     Abstract available


    March 2023
  221. COLA JP, Nascimento do Prado T, Alves KBA, Lapa E Silva JR, et al
    Factors associated with non-completion of TB preventive treatment in Brazil.
    Int J Tuberc Lung Dis. 2023;27:215-220.
    PubMed     Abstract available


  222. HUDDART S, Asege L, Jaganath D, Golla M, et al
    Continuous cough monitoring: a novel digital biomarker for TB diagnosis and treatment response monitoring.
    Int J Tuberc Lung Dis. 2023;27:221-222.
    PubMed    


  223. YAACOUB H, Farhat AM, Najjar-Pellet J, Zgheib J, et al
    Planning for TB elimination in Lebanon.
    Int J Tuberc Lung Dis. 2023;27:171-174.
    PubMed    


  224. KWON YS, Jang JG, Lee J, Choi KJ, et al
    Risk factors for peripheral neuropathy in patients on linezolid-containing regimens for drug-resistant TB.
    Int J Tuberc Lung Dis. 2023;27:232-234.
    PubMed    


  225. PALACIOS CF, Hough MA, Shrestha R, Moll AP, et al
    Perceived stigma related to TB preventive therapy.
    Int J Tuberc Lung Dis. 2023;27:209-214.
    PubMed     Abstract available


  226. AKKERMAN OW, van Het Hof S, de Vries G, van Crevel R, et al
    Characteristics and mortality of central nervous system TB in the Netherlands: a 15-year comparison with other forms of TB.
    Int J Tuberc Lung Dis. 2023;27:237-239.
    PubMed    


  227. HUAROTO L, Huaman MA, Mugruza R, Ticona C, et al
    Active case-finding of pulmonary TB in an urban emergency department.
    Int J Tuberc Lung Dis. 2023;27:202-208.
    PubMed     Abstract available


  228. ADEWOLE OO, Omotoso BA, Ogunsina M, Aminu A, et al
    Atorvastatin accelerates Mycobacterium tuberculosis clearance in pulmonary TB: a randomised phase IIA trial.
    Int J Tuberc Lung Dis. 2023;27:226-228.
    PubMed    


  229. MALIK AA, Jaswal M, Siddiqui S, Amanullah F, et al
    Role of symptom and chest X-ray screening in evaluating child household contacts for pulmonary TB.
    Int J Tuberc Lung Dis. 2023;27:235-236.
    PubMed    


  230. TRAUER JM
    Targeted TB control in migrants to low-burden countries.
    Int J Tuberc Lung Dis. 2023;27:169-170.
    PubMed    


  231. MARTINEZ-GARCIA MA, Guan WJ, de-la-Rosa D, Athanazio R, et al
    Post-TB bronchiectasis: from pathogenesis to rehabilitation.
    Int J Tuberc Lung Dis. 2023;27:175-181.
    PubMed     Abstract available


  232. TANEJA R, Nahata MC, Scarim J, Pande PG, et al
    Stable, compounded bedaquiline suspensions to support practical implementation of pediatric dosing in the field.
    Int J Tuberc Lung Dis. 2023;27:189-194.
    PubMed     Abstract available


  233. DAMARAJU V, Singh N, Garg M, Kathirvel S, et al
    Effect of prior pulmonary TB on low-dose computed tomography during lung cancer screening.
    Int J Tuberc Lung Dis. 2023;27:223-225.
    PubMed    


  234. SPRUIJT I, Erkens C, Greenaway C, Mulder C, et al
    Reducing the burden of TB among migrants to low TB incidence countries.
    Int J Tuberc Lung Dis. 2023;27:182-188.
    PubMed     Abstract available


  235. BAIK Y, Nakasolya O, Isooba D, Mukiibi J, et al
    Cost to perform door-to-door universal sputum screening for TB in a high-burden community.
    Int J Tuberc Lung Dis. 2023;27:195-201.
    PubMed     Abstract available


    February 2023
  236. CHUNG C, Shin JE, Jeon D, Kang H, et al
    Treatment outcomes and safety of bedaquiline, delamanid, and linezolid in multidrug-resistant TB.
    Int J Tuberc Lung Dis. 2023;27:151-153.
    PubMed    


  237. GOMES I, Garg T, Churchyard G, Gupta A, et al
    The cascade of care for household contacts of people with drug-resistant TB.
    Int J Tuberc Lung Dis. 2023;27:154-156.
    PubMed    


  238. TOCHAENG C, Eksombatchai D, Boonsarngsuk V
    Factors associated with false-negative for T-SPOT.TB in patients with TB disease.
    Int J Tuberc Lung Dis. 2023;27:128-134.
    PubMed     Abstract available


  239. ALKABAB Y, Warkentin J, Cummins J, Katz B, et al
    Therapeutic drug monitoring and TB treatment outcomes in patients with diabetes mellitus.
    Int J Tuberc Lung Dis. 2023;27:135-139.
    PubMed     Abstract available


  240. FORSMAN LD, Alffenaar JWC
    Diabetes mellitus and TB - finding strategies to reduce the double burden of disease.
    Int J Tuberc Lung Dis. 2023;27:91-93.
    PubMed    


  241. BARKER M, Gunther A, Wurps H, Gebhardt A, et al
    Ultrasound-guided lymph node biopsy in smear-negative children and adolescents with suspected TB.
    Int J Tuberc Lung Dis. 2023;27:164-165.
    PubMed    


  242. BOLSTERLI E, Keller PM, Suter-Riniker F, Kruger L, et al
    A comparison of bronchoalveolar lavage and gastric aspirate for diagnosis of paediatric TB.
    Int J Tuberc Lung Dis. 2023;27:148-150.
    PubMed    


  243. VILLA S, Carugati M, Rubach MP, Cleaveland S, et al
    'One Health approach to end zoonotic TB.
    Int J Tuberc Lung Dis. 2023;27:101-105.
    PubMed     Abstract available


  244. BALTAS I, Sturdy A, Kavallieros K, McGregor A, et al
    Diabetes mellitus is not a predictor of poor TB treatment outcomes.
    Int J Tuberc Lung Dis. 2023;27:140-145.
    PubMed     Abstract available


  245. CHUKWUOGO O, Odume B, Ogbudebe C, Useni S, et al
    Strategic approach to optimisation of TB contact investigation in Nigeria.
    Int J Tuberc Lung Dis. 2023;27:161-163.
    PubMed    


  246. PAUDEL K, Nalutaaya A, Robsky KO, Kitonsa PJ, et al
    The impact of time at home on potential yield of home-based TB contact investigation.
    Int J Tuberc Lung Dis. 2023;27:121-127.
    PubMed     Abstract available


  247. KOESOEMADINATA RC, McAllister SM, Soetedjo NNM, Santoso P, et al
    Diabetes characteristics and long-term management needs in diabetic TB patients.
    Int J Tuberc Lung Dis. 2023;27:113-120.
    PubMed     Abstract available


  248. TANEJA R, Nahata MC, Scarim J, Pande PG, et al
    Extemporaneously compounded liquid formulations of clofazimine.
    Int J Tuberc Lung Dis. 2023;27:106-112.
    PubMed     Abstract available


  249. GENADE LP, Kahamba T, Scott L, Tempia S, et al
    Co-testing a single sputum specimen for TB and SARS-CoV-2.
    Int J Tuberc Lung Dis. 2023;27:146-147.
    PubMed    


    January 2023
  250. KHAN U, Guglielmetti L
    Tailored TPT for drug-resistant TB - promoting equity and access to optimal care.
    Int J Tuberc Lung Dis. 2023;27:89b-90.
    PubMed    


  251. MANSOOR H, Hirani N, Chavan V, Das M, et al
    Clinical utility of target-based next-generation sequencing for drug-resistant TB.
    Int J Tuberc Lung Dis. 2023;27:41-48.
    PubMed     Abstract available


  252. GILLESPIE SH
    Improving outcomes for multidrug-resistant TB: the role of integrated systems.
    Int J Tuberc Lung Dis. 2023;27:1-2.
    PubMed    


  253. SEHGAL IS, Muthu V, Agarwal R
    Aspergillus infection is an important complication of post-TB bronchiectasis.
    Int J Tuberc Lung Dis. 2023;27:89a-89.
    PubMed    


  254. OLARU ID, Beliz Meier M, Schumacher SG, Prodanovic N, et al
    Co-administration of treatment for drug-resistant TB and hepatitis C.
    Int J Tuberc Lung Dis. 2023;27:66-68.
    PubMed    


  255. FELKER I, Trajman A
    Shorter regimens for multidrug-/rifampicin-resistant TB.
    Int J Tuberc Lung Dis. 2023;27:3-4.
    PubMed    


  256. KWON YS, Shin JE, Kang H, Jeon D, et al
    Treatment outcomes of multidrug-resistant TB with selective use of new drugs.
    Int J Tuberc Lung Dis. 2023;27:55-60.
    PubMed     Abstract available


  257. ZENG C, Mitnick CD, Hewison C, Bastard M, et al
    Concordance of three approaches for operationalizing outcome definitions for multidrug-resistant TB.
    Int J Tuberc Lung Dis. 2023;27:34-40.
    PubMed     Abstract available


  258. CANTERA JL, Rashid AA, Lillis LM, Peck RB, et al
    Isolation and purification of lipoarabinomannan from urine of adults with active TB.
    Int J Tuberc Lung Dis. 2023;27:75-77.
    PubMed    


  259. KNUDSEN S, Babu SP, Ramakrishnan J, Jenkins HE, et al
    M. tuberculosis infection before, during and after pregnancy.
    Int J Tuberc Lung Dis. 2023;27:72-74.
    PubMed    


  260. ATSHEMYAN H, Khachatryan N, Manukyan A, Khachatryan A, et al
    Implementation of modified, all-oral shorter TB regimens in Armenia.
    Int J Tuberc Lung Dis. 2023;27:84-85.
    PubMed    


  261. BUTOV D, Feshchenko Y, Chesov D, Myasoedov V, et al
    National survey on the impact of the war in Ukraine on TB diagnostics and treatment services in 2022.
    Int J Tuberc Lung Dis. 2023;27:86-88.
    PubMed    


  262. TANEJA R, Nahata MC, Scarim J, Pande PG, et al
    Sugar and sugar-free liquid formulations of delamanid for patients with rifampicin-resistant TB.
    Int J Tuberc Lung Dis. 2023;27:13-18.
    PubMed     Abstract available


  263. MAH JK, Lieu A, Fisher D, Lim RK, et al
    Impact of the COVID-19 pandemic on the epidemiology of TB in a low-incidence setting.
    Int J Tuberc Lung Dis. 2023;27:69-71.
    PubMed    


  264. COX SR, Padmapriyadarsini C, Mave V, Seth B, et al
    Characterising cause of death among people treated for drug-susceptible TB in India.
    Int J Tuberc Lung Dis. 2023;27:78-80.
    PubMed    


  265. JAW-TSAI S, Barry R, Pande PG, Taneja R, et al
    Comparison of pharmacokinetics and bioavailability of bedaquiline fumarate, benzoate and maleate in dogs.
    Int J Tuberc Lung Dis. 2023;27:28-33.
    PubMed     Abstract available


  266. DE HAAS P, Nhung NV, Hng NT, Hoa NB, et al
    Introduction of the Simple One-Step stool Xpert Ultra method to detect TB in children and adults.
    Int J Tuberc Lung Dis. 2023;27:19-27.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Tuberculosis is free of charge.